China’s Livongo Incarey Closes Series B+ at USD 30 Mn
Zhejiang InCarey is a chain pharmacy providing specialty medicines for critical and chronic diseases. The company recently closed Series B+ at USD 30 million to further build the online service system for chronic illness and cover a bigger patient pool.
Livongo, the US health management platform for chronic disease, was founded in 2018 and went public in 2019. It mainly produces long-term health solutions for patients and solves insurance reimbursement demand for US private insurance companies. It took six years to reach the market value of USD 10 billion.
InCarey, learning from Livongo, built a Chinese-Style business model and focuses on the Chinese chronic disease health management market of CNY 500 billion.